Business
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology – – Underscores the value of recent Evoke acquisition that builds upon Firefly's FDA-cleared BNA™ AI platform and unique integrated normative reference group – – It’s well accepted that earlier dementia course detection can improve outcomes and
About this update from Firefly Neuroscience, Inc.
[{"type":"image","alt":"Firefly Neuroscience, Inc.","displaySize":"","headline":null,"caption":"Firefly Neuroscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":108,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/65ce4f4d20d9020a27b26140260a562c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4hVXp0E9TNkw24EguQWRjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTE0MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/65ce4f4d20d9020a27b26140260a562c","width":108,"height":73}},"lazy":false},{"type":"text","content":"– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia –","length":115,"tagName":"p"},{"type":"text","content":"– Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology – ","length":141,"tagName":"p"},{"type":"text","content":"– Underscores the value of recent Evoke acquisition that builds upon Firefly's FDA-cleared BNA™ AI platform and unique integrated normative reference group –","length":161,"tagName":"p"},{"type":"text","content":"– It’s well accepted that earlier dementia course detection can improve outcomes and open up additional treatment opportunities –","length":129,"tagName":"p"},{"type":"text","content":"KENMORE, N.Y., June 20, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today highlighted a leap forward in Alzheimer’s research to distinguish between subjective cognitive decline (“SCD”), mild cognitive impairment (“MCI”), and dementia in a scalable, accessible way to promote earlier detection and intervention.","length":525,"tagName":"p"},{"type":"text","content":"In the study, while EEG/ERP and volumetric magnetic resonance imaging (“vMRI”) each helped alone, the best results came when both were combined. Just using EEG measures, three EEG measures stood out: (1) reaction time; (2) commission errors; and (3), P300b amplitude. Using these EEG assessments, researchers could categorize subjects with ~80% accuracy (AUC = 0.79). With respect to vMRI assessment, of all the brain areas, only the left temporal lobe size was a powerful MRI...